Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

at (ITT) population from the two randomized Phase 3 studies. Researchers used fixed-effects meta-analysis and Cox regression models to complete the analysis, fixing the time of the 8-12 day primary end of therapy assessment utilized in the clinical trials at 12 days.

Additional Study Results

In the two Phase 3 studies, DIFICID achieved clinical cure rates at the end of treatment that were non-inferior to oral vancomycin and lower recurrence rates that were statistically significant. In the ITT analysis, the superior reduction in persistent diarrhea or death seen at day 12 for DIFICID (p=0.037) was driven by 7 deaths among DIFICID-treated patients (1.2%) compared to 17 (2.9%) deaths among patients who received vancomycin (exact p=0.06). The overall analysis demonstrated a 40% reduction in persistent diarrhea, disease recurrence or death (all causes) compared to vancomycin through day 40 of the study (95% CI: 26-51%; p<0.0001).

Results of the ITT combined analysis also show that randomization to DIFICID in the Phase 3 clinical studies reduced the risk of persistent diarrhea, recurrence or death by 52% (95% CI: 37-63%; p<0.0001), even after adjusting for other factors. Persistent diarrhea or death in the first 12 days following initiation of treatment was most strongly predicted by previous anti-CDAD antibiotic use in the 24 hours prior to randomization (p=0.0001) and low baseline eosinophils (p=0.007) and/or albumin (p<0.0001) at randomization. Patients with CDAD in the three months prior to entering the study had a 68% higher risk of recurrence or death during study days 13-40. Through 40 days, there was no evidence that the benefits of DIFICID over vancomycin varied according to disease severity, prior history of CDAD, previous anti-CDAD antibiotics, inpatient versus outpatient, patient age, baseline albumin or baseline creatinine levels.

About CDAD

Clostridium difficile-associated diarrhea (CDAD) ha
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  New technologies and online ... to educate themselves about products and companies. Likewise, ... techniques available to market researchers seeking insights into ... marketplace, it,s imperative that organizations adjust their consumer ... market opportunities, niches and growth fronts. ...
(Date:4/24/2015)... , Apr. 24, 2015 Research and Markets ... the "Global Biobanking Market 2015-2019" report to ... Biobanking market to grow at a CAGR of 7.07% ... market can be divided into two segments: Equipment and ... growth prospects of the Global Biobanking market for the ...
(Date:4/24/2015)... Hi-Tech Pharmaceuticals refutes the results from ... of reliable scientific principles and methods and therefore ... of adulteration. The FDA is resting its very, ... misguided hope, that Methylphenylethylamine is not found in ... multiple other studies and cannot be relied on ...
Breaking Medicine Technology:Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6
(Date:4/24/2015)... KY (PRWEB) April 24, 2015 Anchor ... for Medical Field Professionals, today announced their exclusive agreement ... national Long Term Care Insurance distribution partner. , Anchor ... Long Term Care Insurance benefits for associations, and is ... for its Long Term Care Insurance member benefit. ...
(Date:4/24/2015)... 2015 “Kind,” “selfless,” “the voice of ... ways Denise Weiner described pediatric oncology nurse Laura Vasquez ... daughter, Alexa, during her five-year battle with a malignant ... marrow transplant and numerous experimental treatments, Vasquez continued caring ... when she was not in the hospital and even ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... MMJ Physician Practice in Salem, ... to enroll in the Massachusetts medical marijuana program.    Their ... away from Alternative Therapies Group (ATG), the first ... summer. With the dispensary nearby, MMJ Physician ... for residents of eastern Massachusetts to enroll in ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Qualis ... management organizations, has published a new resource for ... Guide.” The guide to Quality and Resource Use ... Medicaid & Medicare Services (CMS) to help practices ... care, streamline resources, and identify care coordination opportunities ...
Breaking Medicine News(10 mins):Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Medical Doctor from Salem Massachusetts Supports the Medical Marijuana Industry 2Health News:Qualis Health Publishes Guide to Help Physician Practices Assess and Improve Quality 2
... HealthDay Reporter , WEDNESDAY, March 23 (HealthDay ... of predicting when breast cancer will spread. Two ... distinguish more aggressive cancers from less aggressive ones, according ... not involve changes to the sequencing of the genes ...
... ANGELESBefore undergoing elective surgery, patients should consider waiting longer after ... study scheduled for publication in the May issue of the ... Association and the American College of Cardiology recommend patients wait ... before undergoing elective surgery. This guidance is based on studies ...
... , WEDNESDAY, March 23 (HealthDay News) -- People with ... bronchodilators to control symptoms and reduce flare-ups, but which ... Now results have arrived from a new study that ... to determine their effectiveness at controlling the disease, which ...
... By Ellin Holohan HealthDay Reporter , WEDNESDAY, March ... they weigh less than they do, and many mothers of ... finds. The study of women and children conducted at ... faulty body image was far more prevalent among the heaviest ...
... Reporter , WEDNESDAY, March 23 (HealthDay News) -- The Affordable ... health-care reform package -- the centerpiece of President Barack Obama,s ... day it was signed into law. "The worst law ... of Consumers for Health Care Choices, a national nonprofit group ...
... hematologist Edward J. Benz Jr., M.D., is the 2011 recipient ... Women in Cancer Medicine and Cancer Science presented by The ... and chief executive officer of Dana-Farber Cancer Institute, receives the ... The first male recipient of the Kripke Legend Award, ...
Cached Medicine News:Health News:Genes' 'On/Off' Switches Yield Clues to Breast Cancer 2Health News:Genes' 'On/Off' Switches Yield Clues to Breast Cancer 3Health News:Outcomes improved by longer delays between heart attacks and elective surgeries 2Health News:For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial 2Health News:For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial 3Health News:Many Obese Moms and Kids Underestimate Their Weight 2Health News:Many Obese Moms and Kids Underestimate Their Weight 3Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 2Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 3Health News:As Health Care Reform Turns 1, Backers and Detractors Dig In 4Health News:Benz wins Kripke Award for promoting women in science, medical careers 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: